All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
JAK inhibitors for MF: Individualizing treatment selection
Bookmark this article
|
Four JAKi are currently approved for the treatment of patients with MF in Europe and the USA; ruxolitinib, fedratinib, pacritinib, and momelotinib. Each JAKi has distinct properties which may be suitable for different patient profiles. A recent publication in Blood by Masarova and Chifotides discusses the optimization of JAKi treatment selection for patients with MF.1
|
| Key learnings |
| For patients with MF and adequate platelet counts, ruxolitinib is the preferred first-line treatment due to its robust efficacy; it can control splenomegaly and constitutional symptoms and extend OS. |
| Fedratinib is typically used in second-line settings. It has demonstrated strong symptom control; however, there is a higher risk of GI side effects. |
| Pacritinib and momelotinib are less myelosuppressive and crucial for patients with MF and severe thrombocytopenia or anemia. Momelotinib is uniquely beneficial as it reduces transfusion dependence, which is linked to improved survival. |
| Individualizing JAKi therapy based on cytopenia severity and dominant symptoms, such as splenomegaly or anemia, can optimize patient outcomes. |
| Expanding treatment options enables more personalized and effective management strategies for MF to improve survival and QoL. |
Abbreviations: GI, gastrointestinal; JAKi, Janus kinase inhibitor; MF, myelofibrosis; MPN, myeloproliferative neoplasm; OS, overall survival; QoL, quality of life.
- Masarova L, Chifotides HT. How I individualize selection of JAK inhibitors for patients with myelofibrosis. 2024. Online ahead of print. DOI: 10.1182/blood.2023022415
Your opinion matters
9 votes - 2 days left ...
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox